Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association

被引:2620
作者
Heidenreich, Paul A.
Trogdon, Justin G.
Khavjou, Olga A.
Butler, Javed
Dracup, Kathleen
Ezekowitz, Michael D.
Finkelstein, Eric Andrew
Hong, Yuling
Johnston, S. Claiborne
Khera, Amit
Lloyd-Jones, Donald M.
Nelson, Sue A.
Nichol, Graham
Orenstein, Diane
Wilson, Peter W. F.
Woo, Y. Joseph
机构
关键词
AHA Scientific Statements; cardiovascular diseases; forecasting; US costs; cost analysis; COLLEGE-OF-CARDIOLOGY; ACUTE MYOCARDIAL-INFARCTION; RISK-FACTOR PROFILE; PRIMARY PREVENTION; ADOLESCENT OVERWEIGHT; PERFORMANCE-MEASURES; ECONOMIC BURDEN; BLOOD-PRESSURE; TASK-FORCE; ADULT;
D O I
10.1161/CIR.0b013e31820a55f5
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background-Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results-To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. Conclusions-These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD. (Circulation. 2011;123:933-944.)
引用
收藏
页码:933 / 944
页数:12
相关论文
共 77 条
[1]
*AM ASS MED COLL, 2006, AAMC CALLS 30 PERC I
[2]
[Anonymous], 2005, MMWR, V54, P1
[3]
[Anonymous], LONG TERM BUDG OUTL
[4]
[Anonymous], 2005, PHYS WORKF POL GUID
[5]
[Anonymous], 2010, HLTH US 2009 SPEC FE
[6]
[Anonymous], 2006, COST OF ILLNESS STUD
[7]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[8]
RACIAL-DIFFERENCES IN THE INCIDENCE OF CARDIAC-ARREST AND SUBSEQUENT SURVIVAL [J].
BECKER, LB ;
HAN, BH ;
MEYER, PM ;
WRIGHT, FA ;
RHODES, KV ;
SMITH, DW ;
BARRETT, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (09) :600-606
[9]
Adolescent overweight and future adult coronary heart disease [J].
Bibbins-Domingo, Kirsten ;
Coxson, Pamela ;
Pletcher, Mark J. ;
Lightwood, James ;
Goldman, Lee .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (23) :2371-2379
[10]
Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease [J].
Bibbins-Domingo, Kirsten ;
Chertow, Glenn M. ;
Coxson, Pamela G. ;
Moran, Andrew ;
Lightwood, James M. ;
Pletcher, Mark J. ;
Goldman, Lee .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (07) :590-599